Sterling Capital Management LLC boosted its holdings in shares of Humana Inc (NYSE:HUM) by 1,316.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 14,858 shares of the insurance provider’s stock after buying an additional 13,809 shares during the quarter. Sterling Capital Management LLC’s holdings in Humana were worth $3,620,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in HUM. Advisors Asset Management Inc. grew its position in Humana by 16.5% during the second quarter. Advisors Asset Management Inc. now owns 3,124 shares of the insurance provider’s stock valued at $752,000 after buying an additional 443 shares during the period. Dupont Capital Management Corp grew its position in Humana by 54.9% during the second quarter. Dupont Capital Management Corp now owns 10,902 shares of the insurance provider’s stock valued at $2,623,000 after buying an additional 3,866 shares during the period. Alps Advisors Inc. bought a new stake in Humana during the second quarter valued at approximately $295,000. Legal & General Group Plc grew its position in Humana by 4.0% during the second quarter. Legal & General Group Plc now owns 821,442 shares of the insurance provider’s stock valued at $197,660,000 after buying an additional 31,842 shares during the period. Finally, Gamco Investors INC. ET AL grew its position in Humana by 36.2% during the second quarter. Gamco Investors INC. ET AL now owns 5,175 shares of the insurance provider’s stock valued at $1,245,000 after buying an additional 1,375 shares during the period. Institutional investors own 94.19% of the company’s stock.
Humana Inc (NYSE HUM) opened at $253.64 on Friday. The firm has a market cap of $35,802.17, a P/E ratio of 21.38, a price-to-earnings-growth ratio of 1.72 and a beta of 0.88. Humana Inc has a 12-month low of $186.25 and a 12-month high of $264.56. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.61 and a quick ratio of 1.61.
Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.27 by $0.12. The business had revenue of $13.28 billion during the quarter, compared to analyst estimates of $13.41 billion. Humana had a net margin of 3.49% and a return on equity of 15.99%. The company’s revenue was down 3.0% on a year-over-year basis. During the same period in the prior year, the business posted $3.18 earnings per share. sell-side analysts anticipate that Humana Inc will post 11.63 EPS for the current year.
Humana declared that its board has approved a stock repurchase program on Thursday, December 14th that authorizes the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization authorizes the insurance provider to buy shares of its stock through open market purchases. Shares repurchase programs are typically a sign that the company’s board believes its shares are undervalued.
The business also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 0.63%. The ex-dividend date of this dividend is Thursday, December 28th. Humana’s dividend payout ratio (DPR) is presently 12.59%.
Several analysts recently issued reports on HUM shares. BMO Capital Markets boosted their target price on shares of Humana from $290.00 to $300.00 and gave the company an “outperform” rating in a research report on Friday, November 10th. ValuEngine upgraded shares of Humana from a “hold” rating to a “buy” rating in a research report on Friday, September 1st. Royal Bank of Canada restated a “sector perform” rating and set a $242.00 target price (down from $245.00) on shares of Humana in a research report on Thursday, November 9th. Credit Suisse Group cut their target price on shares of Humana from $256.00 to $246.00 and set a “neutral” rating for the company in a research report on Friday, November 10th. Finally, Zacks Investment Research lowered shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Twelve equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $256.30.
TRADEMARK VIOLATION NOTICE: “Humana Inc (HUM) Shares Bought by Sterling Capital Management LLC” was originally published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.truebluetribune.com/2017/12/16/humana-inc-hum-shares-bought-by-sterling-capital-management-llc.html.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.